Article in American journal of medical genetics. Part A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Ji Yun TarkSection of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-3233-5967
Alexander RenwickSection of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Giorgio TettamantiUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-5210-7219
Rachel D HarrisDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-8191-5477
Tania A DesrosiersDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Andrew F OlshanDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Amanda E JanitzDepartment of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA.ORCID 0000-0003-2690-385X
Michael E ScheurerDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Charles J ShumateBirth Defects Epidemiology and Surveillance Branch, Texas Department of State Health Services, Austin, Texas, USA.ORCID 0000-0003-2884-2835
Angela E ScheuerleDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Sharon E PlonDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Chad D HuffDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ann NordgrenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3285-4281
Barbara LukeDepartment of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.ORCID 0000-0002-0405-8133
Philip J LupoDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Jeremy M SchrawDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-6674-9562
Funding
Qualification and Deployment of Imaging Biomarkers of Cancer Treatment ResponseU01CA190214 · NCI · STANFORD UNIVERSITY · PI RUBIN, DANIEL L · 2015 to 2020
$3.1M
A US-UK Collaborative Study of the Health of Children Born From In Vitro Fertilization: From Conception Through Young AdulthoodR01HD112081 · NICHD · EMORY UNIVERSITY · PI BARBARA JOAN LUKE, Philip Lupo · 2023 to 2026
$2.3M
Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric CancerR01CA284531 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Chad Daniel Huff, Philip Lupo · 2023 to 2026
$1.9M
Cancer Prevention and Research Institute of Texas RP210037National Institute of Child Health and Human Development R01HD112081NCI NIH HHS 1R01CA284531NCI NIH HHS R01 CA284531NCI NIH HHS U01 CA190214NICHD NIH HHS R01 HD112081Rally Foundation 23CND05U.S. Department of Defense CA190214
6 · The paper itself
Abstract
Cancer risk in children with VACTERL, a nonrandom co-occurrence of ≥ 3 defects (vertebral, anal, cardiac, tracheoesophogeal fistula, renal, and limb), remains unclear. We evaluated this association in a population-based study. We analyzed data from the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Study, a US registry linkage cohort. VACTERL was defined as the presence of ≥ 3 associated defects. Cox regression was applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer risk before age 18 in children with VACTERL compared to children without birth defects. Kaplan-Meier analyses were used to estimate cumulative incidence of cancer in each group. Of 21,224,742 births, 2288 met VACTERL criteria; 8 developed cancer, 5 (63%) of whom were diagnosed with embryonal tumors. Children with VACTERL had a significantly increased cancer risk (HR = 3.0, 95% CI: 1.5-6.0), particularly for embryonal tumors (HR = 6.9, 95% CI: 2.9-16.5), relative to unaffected children. Cancer incidence was 421.3 (95% CI: 181.9, 830.0) per million person-years for VACTERL versus 133.4 (95% CI: 131.8-135.0) for unaffected children. Children with VACTERL may face increased cancer risk. Shared developmental or epigenetic mechanisms may underlie both conditions, highlighting efforts to identify subgroups that may benefit from targeted surveillance.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Population-Based Assessment of Cancer Risk in Children With VACTERL. · full record | OpenQuestion